The path to first patient dosing
Filed with ASX · · 2 pages · English
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Clinical manufacturing batch released, first site activated
- Arovella Appoints Acting CEO
- Board Refresh and CEO Resignation
- CLDN18.2 CAR iNKT Cell Preclinical Data Update
- Half Year Report and Appendix 4D
Later from Arovella Therapeutics
- Second Clinical Batch Released for Immediate Patient Use
- Arovella receives R&D tax rebate of $4.03 million
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patient Dosed with ALA-101
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics